Healthconn Corp posted Q2 2024 revenue of 298.6 million TWD, down 51.9% year over year from the prior-year quarter, with gross profit of 53.7 million and a gross margin of approximately 18%. The company reported an operating loss of 4.19 million and an EBITDA of 2.02 million, yielding an EBITDA margin near 0.68%. Net income reached 0.11 million, translating to a thin net margin of about 0.036% for the quarter, while basic earnings per share stood at 0.0023 TWD. Despite a sharp revenue decline, the company delivered a modest year-over-year improvement in net income, supported by otherwise positive non-operating items and a favorable tax line on a quarterly basis. Cash flow metrics remained challenging: operating cash flow was negative (-14.7 million), and free cash flow was negative (-17.3 million), contributing to a net decrease in cash for the period; however, the balance sheet reflects robust liquidity with significant cash and short-term investments, suggesting substantial headroom for strategic investments or working capital optimization. The divergence between reported cash flow weakness and a solid cash position warrants close attention to working capital dynamics and potential one-off effects in the quarter.